|
| Press Releases |
|
 |
|
| Tuesday, August 1, 2023 |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
|
iTolerance, Inc. and Northway Biotech Announce Partnership Agreement for Manufacturing of Streptavidin-FasL Fusion Protein for Innovative iTOL-100 Immunomodulatory Technology |
| iTOL-100 technology has broad applicability and can be applied to both allogenic and stem cell-derived organoids across a number of diseases. Manufacturing agreement supports advancement of iTolerance's development of iTOL-100 towards first in human clinical study for lead program, iTOL-102. more info >> |
|
| Thursday, May 25, 2023 |
|
|
Northway Biotech Set to Launch Advanced Microbial and Mammalian GMP Facilities in Massachusetts |
| Northway Biotech, a biopharmaceutical contract development and manufacturing organization (CDMO), established in 2004, with an EMA and FDA-compliant, state-of-the-art cGMP manufacturing site in Vilnius, Lithuania, announced the completion of its expansion project for cGMP manufacturing facilities in Waltham, Massachusetts. This significant accomplishment further solidifies Northway Biotech's standing as an influential player in the global biopharmaceutical landscape. more info >> |
|
| Wednesday, May 17, 2023 |
|
|
tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat |
| tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
18th Asian Financial Forum wraps up successfully
Jan 15, 2025 14:10 JST
|
|
|
YESIANG Enterprise、革新的なグリーン技術でグローバルな持続可能性推進をリード
Jan 15, 2025 13:00: JST
|
|
|
Fujitsu, Resona Bank and Saitama Resona Bank launch new web service to simplify home-buying process
Jan 15, 2025 13:13 JST
|
|
|
三菱重工、東京都交通局の日暮里・舎人ライナー向けで330形車両12編成（60両）を完納
Jan 15, 2025 10:30: JST
|
|
|
TANAKA's Group Company EEJA to Exhibit at 39th NEPCON JAPAN
Jan 15, 2025 11:00 JST
|
|
|
FDA Accepts LEQEMBI (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Jan 15, 2025 10:03 JST
|
|
|
Bedding Industries of America Unveils Glacier: The Ultimate Hybrid Cooling Mattress
Jan 15, 2025 00:42: JST
|
|
|
Bedding Industries of America Unveils Glacier: The Ultimate Hybrid Cooling Mattress
Jan 14, 2025 23:42 HKT/SGT
|
|
|
富士通、「コーポレートガバナンス・オブ・ザ・イヤー2024」で「Grand Prize Company（大賞）」を受賞
Jan 14, 2025 13:40: JST
|
|
|
Swiss WEB3FEST Winter Edition 2025
Jan 14, 2025 11:01 HKT/SGT
|
|
|
One-Hour Payouts: Hola Prime Solves Prop Trading's Biggest Problem
Jan 14, 2025 11:00: JST
|
|
|
One-Hour Payouts: Hola Prime Solves Prop Trading's Biggest Problem
Jan 14, 2025 10:00 HKT/SGT
|
|
|
エーザイとバイオジェン・インク、早期アルツハイマー病治療剤「レケンビ(R)」の皮下注射製剤維持投与に関する 生物製剤承認申請を米国FDAが受理
Jan 14, 2025 10:00: JST
|
|
|
Investing in Tomorrow: Winvest Group Opens Up Metaverse Opportunities
Jan 13, 2025 23:00: JST
|
|
|
Investing in Tomorrow: Winvest Group Opens Up Metaverse Opportunities
Jan 13, 2025 23:00 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
